title: Bortezomib for effective treatment of a child with refractory autoimmune hemolytic anemia post allogeneic hematopoietic stem cell transplant.
authors.affiliation: Division of Hematology, Oncology, Blood and Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, California.
authors.forename: Bhakti
authors.initials: B
authors.lastname: Mehta
authors.forename: Kris
authors.initials: K
authors.lastname: Mahadeo
authors.forename: Re
authors.initials: R
authors.lastname: Zaw
authors.forename: Shinyi
authors.initials: S
authors.lastname: Tang
authors.forename: Neena
authors.initials: N
authors.lastname: Kapoor
authors.forename: Hisham
authors.initials: H
authors.lastname: Abdel-Azim
mesh_terms: D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy* / Q000209:etiology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007223:Infant; D008297:Male; D011379:Prognosis; D011719:Pyrazines / Q000627:therapeutic use*; D016511:Severe Combined Immunodeficiency / Q000150:complications* / Q000628:therapy; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib